Effects of rhGM-CSF on myeloid clonogenic cells in acute myelogenous leukemia patients.
The effects of rhGM-CSF in vivo on the myeloid clonogenic cells present in 6 AML patients was evaluated. The relative number of clonogenic cells fell in 4 of the 6 patients. The effects of rhGM-CSF on the percentage of clonogenic cells in S phase and the sensitivity of clonogenic cells to cytosine arabinoside varied among the patients. These effects were not related to the effects of rhGM-CSF on the white blood cell count or on the proliferative rate of the leukemia cell population as a whole.
Preisler
H
H
University of Cincinnati Medical Center, Ohio 45267-0508.
Larson
R
R
Banavali
S
S
Yin
M
M
Li
Y Q
YQ
Banerjee
M
M
Gopal
V
V
Raza
A
A
D000328:Adult; D000368:Aged; D001773:Blood Cells / Q000187:drug effects; D001853:Bone Marrow / Q000473:pathology; D002999:Clone Cells / Q000187:drug effects; D003561:Cytarabine / Q000494:pharmacology; D015973:Gene Expression Regulation, Leukemic; D016259:Genes, myc; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D009857:Oncogenes; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D016196:S Phase / Q000187:drug effects; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000473:pathology; D014410:Tumor Stem Cell Assay
D007155:Immunologic Factors; D011994:Recombinant Proteins; D003561:Cytarabine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor